Anthem Biosciences Reports Profit Surge to Rs 211 Crore

Profit rose to Rs 211.46 crore; Revenue grew to Rs 594.03 crore for the September 2026 quarter.

Reader Takeaway: Revenue growth in the CRDMO segment drove quarterly profit, though half-year revenue remains slightly lower than last year.

What just happened

Anthem Biosciences released its unaudited consolidated financial results for the quarter ended September 30, 2026. The company reported a net profit after tax of Rs 211.46 crore, compared to Rs 173.43 crore in the corresponding quarter of the previous year. Revenue from operations reached Rs 594.03 crore, reflecting steady growth from the Rs 550.50 crore reported in Q2 of the previous fiscal year.

Why this matters

The results demonstrate stability in the company’s core business segments: Contract Research, Development and Manufacturing Organization (CRDMO) and Speciality Ingredients. While total revenue for the half-year stands at Rs 1,012.25 crore—a slight decline from the Rs 1,091.37 crore seen in the same period last year—profitability for the half-year grew to Rs 331.40 crore compared to Rs 309.22 crore, suggesting improved operational efficiency.

Corporate Developments

The company completed an allotment of 143,285 equity shares under its Employee Stock Option Plan 2024. Additionally, shareholders had previously approved a final dividend of Rs 2 per share for the 2025-26 fiscal year during the Annual General Meeting held in July 2026.

Governance and Audit

The financial statements were reviewed by S.R. Batliboi & Associates LLP. The auditors issued an unmodified review report, stating that no material misstatements were identified during their assessment of the standalone and consolidated financials.

What to track next

Investors should monitor the revenue trajectory across the CRDMO segment, which remains a primary growth driver for the firm, and assess whether the half-year revenue dip is a temporary trend or an indicator of changing market demand in the Speciality Ingredients sector.